SMN2 and spinal muscular atrophy, type 1: Santobono-Pausilipon in Naples, a reference center in the Campania Region for the diagnosis and management of SMA, was identified as a prescribing center for onasemnogene abeparvovec for the treatment, within the first 6 months of life, of patients with a genetic diagnosis of SMA type 1 (bi-allelic mutation in the SMN1 gene and up to 2 copies of the SMN2 gene) or with a clinical diagnosis of SMA type 1, in accordance with the law 648 of 23 December 1996.